Search-led Peptide Reference
CJC-1295 DAC vs no DAC: identity and COA verification
Source-based guide to CJC-1295 DAC vs no DAC difference molecular weight COA, with molecular identity, evidence limits, analytical checks and dated regulatory verification.
Direct answer
The highest-value answer is an identity-control workflow, because the names are not interchangeable specifications.
Search engines and AI summaries often collapse aliases, molecule classes, preclinical observations and regulatory events into one confident sentence. A reliable archive record keeps those fields separate and links each claim to a date-stamped primary source.
Name and molecular identity
“CJC-1295” is used inconsistently for a Drug Affinity Complex conjugate and for shorter-acting material often labeled no DAC or Mod GRF(1-29).
Require the full construct, conjugation statement, expected mass, LC-MS evidence, HPLC method, content basis and lot-linked chromatogram.
| Identity field | What to verify |
|---|---|
| Name and aliases | Exact spelling, development code and whether an alias is molecule-specific |
| Structure | Sequence or chemical structure, termini, modification and conjugation |
| Molecular form | Free form, salt/counterion, hydration state and calculated mass basis |
| Analytical support | Orthogonal identity, purity, content and lot-linked raw-data references |
How to compare without overclaiming
DAC conjugation changes the declared molecular structure and expected analytical behavior. A shared GHRH-related sequence motif does not make the products equivalent.
Cross-study comparisons require matched populations, models, exposure, duration, endpoints and analysis methods. A receptor label, publication count or high HPLC area percentage cannot by itself establish clinical equivalence, safety, effectiveness or sample identity.
Evidence and status review
When reading older studies, verify which construct was actually administered. Do not infer DAC status from half-life language or a shortened product title.
- Start with the exact name and development code in PubMed and a trial registry.
- Separate biochemical, cellular, animal and human evidence.
- Record the jurisdiction and document date for every regulatory claim.
- Open the primary paper or regulator document instead of citing a search snippet.
- Mark missing sequence, method or lot information as unknown rather than inferred.
COA and procurement-document checklist
- Product name, sequence or structure and declared molecular form agree across label, specification and COA.
- Batch number, test date, method identifier and approval/version fields are present.
- Identity, chromatographic purity and net content are reported as different measurements.
- Chromatogram and mass data correspond to the same lot and are reviewable.
- Water, counterion, residual solvent, elemental or endotoxin tests are included when scientifically relevant.
Primary-source verification routes
Statuses and database records change. Save the document date, jurisdiction, registry identifier and access date; use the primary document for consequential claims.